Biopharmaceutical Performance of DiluCap: A Line of Functional Excipients Enhancing Dissolution Profiles of Minoxidil, Finasteride, Melatonin, and Naltrexone
February 2025
in “
PubMed
”

TLDR DiluCap improves how quickly minoxidil and finasteride dissolve and controls the release of melatonin and naltrexone.
The study evaluates the biopharmaceutical performance of DiluCap®, a line of functional excipients, in enhancing the dissolution profiles of minoxidil, finasteride, melatonin, and naltrexone in hard-shell capsules. The research highlights that minoxidil and finasteride capsules achieved rapid dissolution, while melatonin and naltrexone capsules demonstrated controlled release under gastrointestinal-simulating conditions. These findings emphasize the importance of selecting appropriate excipients to ensure the stability, compatibility, and efficacy of active pharmaceutical ingredients (APIs), thereby enhancing bioavailability and streamlining compounding processes in pharmacies.